Empirical Therapy Versus Tailored Therapy of Helicobacter pylori in Korea: Results of the K‐ CREATE Study
Helicobacter · 2024
DOI: 10.1111/hel.13126 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Helicobacter, 2024. Verfasst von Joon Sung Kim und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori, Anti-Bacterial Agents, Drug Therapy, Combination. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Ministry of Health & Welfare, Republic of Korea.
Abstract (Originalsprache)
Background
The optimal duration of regimens for tailored therapy based on genotypic resistance for clarithromycin has yet to be established.
Aim
This study was a nationwide, multicenter, randomized trial comparing empirical therapy with tailored therapy based on genotypic resistance for first‐line eradication of Helicobacter pylori . We also compared the eradication rates of 7‐ and 14‐day regimens for each group. Patients and Methods Patients with H. pylori infection were first randomized to receive empirical or tailored therapy. Patients in each group were further randomized into 7‐ or 14‐day regimens. Empirical therapy consisted of a triple therapy (TT) regimen (twice‐daily doses of pantoprazole 40 mg, amoxicillin 1 g, and clarithromycin 500 mg) for 7 or 14 days. Tailored therapy consisted of TT of 7 or 14 days in patients without genotypic resistance. Patients with genotypic resistance were treated with bismuth quadruple therapy (BQT) regimens (twice‐daily doses of pantoprazole 40 mg, three daily doses of metronidazole 500 mg, and four times daily doses of bismuth 300 mg and tetracycline 500 mg) for 7 or 14 days. A 13 C‐urea breath test assessed eradication rates. The primary outcome was eradication rates of each group.
Results
A total of 593 patients were included in the study. The eradication rates were 65.7% (201/306) in the empirical therapy group and 81.9% (235/287) in the tailored therapy group for intention‐to‐treat analysis ( p < 0.001). In the per‐protocol analysis, the eradication rates of the empirical therapy and tailored groups were 70.3% (201/286) and 85.5% (235/274) ( p < 0.001), respectively. There was no difference in compliance between the two groups. The rate of adverse events was higher in the tailored group compared to the empirical group ( p < 0.001).
Discussion
Our study confirmed that tailored therapy based on genotypic resistance was more effective than empirical therapy for H. pylori eradication in Korea. However, no significant difference was found between 7‐ and 14‐day regimens for each group. Future studies are needed to determine the optimal duration of therapy for empirical and tailored therapy regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Department of Internal Medicine, St. Vincent Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea.
- Department of Internal Medicine, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Korea.
- Department of Internal Medicine, Pusan National University College of Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
ORCID-Profile: Byung-Wook Kim, Woo Chul Chung, Sung Woo Jung, Chang Seok Bang, Gwang Ha Kim, Seon Woo Jeon, Yun Jeong Lim
Förderung
- Ministry of Health & Welfare, Republic of Korea
Zitieren
APA
Kim, J. S., Kim, B. W., Kim, J. I., Chung, W. C., Jung, S. W., Bang, C. S., Kim, G. H., Jeon, S. W., Joo, M. K., Lee, S. H., Lim, Y. J., Sung, J. K., Seo, S. Y., Park, S. Y., Lee, W. S., Lee, H. L., Kim, K. B., & Kim, H. U. (2024). Empirical Therapy Versus Tailored Therapy of Helicobacter pylori in Korea: Results of the K‐ CREATE Study. Helicobacter. https://doi.org/10.1111/hel.13126
Vancouver
Kim JS, Kim BW, Kim JI, Chung WC, Jung SW, Bang CS, et al. Empirical Therapy Versus Tailored Therapy of Helicobacter pylori in Korea: Results of the K‐ CREATE Study. Helicobacter. 2024. doi:10.1111/hel.13126
BibTeX
@article{Kim2024,
author = {Kim, Joon Sung and Kim, Byung-Wook and Kim, Jin Il and Chung, Woo Chul and Jung, Sung Woo and Bang, Chang Seok and Kim, Gwang Ha and Jeon, Seon Woo and Joo, Moon Kyoung and Lee, Si Hyung and Lim, Yun Jeong and Sung, Jae Kyu and Seo, Seung Young and Park, Sun Young and Lee, Wan Sik and Lee, Hang Lak and Kim, Ki Bae and Kim, Heung Up},
title = {Empirical Therapy Versus Tailored Therapy of Helicobacter pylori in Korea: Results of the K‐ CREATE Study},
journal = {Helicobacter},
year = {2024},
doi = {10.1111/hel.13126}
}
EUVIMED